XKRX326030
Market cap5.54bUSD
Dec 20, Last price
102,100.00KRW
1D
-1.45%
1Q
-6.16%
IPO
-38.12%
Name
SK Biopharmaceuticals Co Ltd
Chart & Performance
Profile
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal; Carisbamate that is in Phase 1b/2 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials to treat rare neurological disease. It is also developing SKL13865 that is in Phase 1 clinical trials to treat attention deficit/hyperactivity disorder; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder; and SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy. The company was founded in 2011 and is headquartered in Seongnam, South Korea. SK Biopharmaceuticals Co., Ltd. operates as subsidiary of SK Inc.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 354,891,556 44.16% | 246,179,120 -41.20% | 418,644,529 1,510.23% | |||||||
Cost of revenue | 286,083,665 | 272,906,388 | 226,663,589 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 68,807,890 | (26,727,268) | 191,980,940 | |||||||
NOPBT Margin | 19.39% | 45.86% | ||||||||
Operating Taxes | (8,478,274) | (3,037,986) | 6,430,908 | |||||||
Tax Rate | 3.35% | |||||||||
NOPAT | 77,286,164 | (23,689,281) | 185,550,032 | |||||||
Net income | (32,882,849) -76.42% | (139,430,878) -315.02% | 64,845,640 -126.21% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 57,060,819 | 5,644,021 | 5,481,443 | |||||||
Long-term debt | 154,554,982 | 162,426,161 | 25,993,590 | |||||||
Deferred revenue | 5 | 31,157,335 | 38,582,218 | |||||||
Other long-term liabilities | 37,702,606 | 3,198,713 | 400 | |||||||
Net debt | (133,593,934) | (35,948,162) | (302,111,832) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (94,201,249) | (159,920,062) | (92,871,733) | |||||||
CAPEX | (3,249,365) | (5,960,948) | (5,991,900) | |||||||
Cash from investing activities | 225,272,591 | (95,713,806) | 258,971,494 | |||||||
Cash from financing activities | 6,622,756 | 134,914,263 | (4,645,850) | |||||||
FCF | 11,790,307 | (46,143,844) | 186,845,700 | |||||||
Balance | ||||||||||
Cash | 241,118,437 | 305,453,733 | 334,339,328 | |||||||
Long term investments | 104,091,298 | (101,435,389) | (752,463) | |||||||
Excess cash | 327,465,157 | 191,709,387 | 312,654,638 | |||||||
Stockholders' equity | (750,654,664) | (780,103,142) | (640,660,135) | |||||||
Invested Capital | 1,287,358,515 | 1,286,707,310 | 1,137,169,878 | |||||||
ROIC | 6.00% | 16.31% | ||||||||
ROCE | 12.78% | 38.49% | ||||||||
EV | ||||||||||
Common stock shares outstanding | 78,313 | 78,313 | 78,313 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | 84,125,334 | (13,743,530) | 203,622,768 | |||||||
EV/EBITDA | ||||||||||
Interest | 8,279,609 | 3,716,526 | 946,984 | |||||||
Interest/NOPBT | 12.03% | 0.49% |